Patents by Inventor Mohammad Luqman
Mohammad Luqman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11886971Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.Type: GrantFiled: August 15, 2019Date of Patent: January 30, 2024Assignee: Microsoft Technology Licensing, LLCInventors: Lekshmi Menon, Amar Budhiraja, Gaurush Hiranandani, Prateek Jain, Darshatkumar Anandji Shah, Ayush Choure, Navya Yarrabelly, Anurag Mishra, Mohammad Luqman, Shivangi Dhakad, Juhi Dua
-
Patent number: 11184301Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.Type: GrantFiled: August 15, 2019Date of Patent: November 23, 2021Assignee: Microsoft Technology Licensing, LLCInventors: Lekshmi Menon, Amar Budhiraja, Gaurush Hiranandani, Prateek Jain, Darshatkumar Anandji Shah, Ayush Choure, Navya Yarrabelly, Anurag Mishra, Mohammad Luqman, Shivangi Dhakad, Juhi Dua
-
Publication number: 20210051121Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.Type: ApplicationFiled: August 15, 2019Publication date: February 18, 2021Inventors: Lekshmi Menon, Amar Budhiraja, Gaurush Hiranandani, Prateek Jain, Darshatkumar Anandji Shah, Ayush Choure, Navya Yarrabelly, Anurag Mishra, Mohammad Luqman, Shivangi Dhakad, Juhi Dua
-
Publication number: 20210049442Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.Type: ApplicationFiled: August 15, 2019Publication date: February 18, 2021Inventors: Lekshmi Menon, Amar Budhiraja, Gaurush Hiranandani, Prateek Jain, Darshatkumar Anandji Shah, Ayush Choure, Navya Yarrabelly, Anurag Mishra, Mohammad Luqman, Shivangi Dhakad, Juhi Dua
-
Publication number: 20170081416Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: August 19, 2016Publication date: March 23, 2017Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman (deceased), Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20150175705Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: ApplicationFiled: March 3, 2015Publication date: June 25, 2015Inventors: Jason Damiano, Mohammad Luqman, Linda Masat, Amer Mirza, Genevieve Nonet, Daniel Bedinger
-
Patent number: 9005614Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: GrantFiled: November 22, 2010Date of Patent: April 14, 2015Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
-
Publication number: 20150086991Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: ApplicationFiled: November 25, 2014Publication date: March 26, 2015Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AGInventors: Sharon Lea Aukerman, Mohammad Luqman
-
Patent number: 8926979Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: GrantFiled: November 1, 2006Date of Patent: January 6, 2015Assignees: Novartis AG, XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Publication number: 20140205602Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: December 19, 2013Publication date: July 24, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20130230528Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: ApplicationFiled: December 17, 2012Publication date: September 5, 2013Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AGInventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Publication number: 20130011405Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: September 12, 2012Publication date: January 10, 2013Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
-
Patent number: 8337851Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: GrantFiled: May 18, 2006Date of Patent: December 25, 2012Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Patent number: 8333970Abstract: Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: GrantFiled: May 18, 2006Date of Patent: December 18, 2012Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Patent number: 8277810Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: GrantFiled: October 31, 2007Date of Patent: October 2, 2012Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20110150760Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: ApplicationFiled: November 22, 2010Publication date: June 23, 2011Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.Inventors: JASON DAMIANO, MOHAMMAD LUQMAN, DANIEL BEDINGER, LINDA MASAT, AMER MIRZA, GENEVIEVE NONET
-
Patent number: 7867493Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: GrantFiled: August 17, 2007Date of Patent: January 11, 2011Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
-
Publication number: 20110002934Abstract: This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.Type: ApplicationFiled: November 7, 2008Publication date: January 6, 2011Inventors: Mohammad Luqman, Sherna Budhabhatti, Yongyu Wang, Seema Kantak, Ssucheng J. Hsu, Amer M. Mirza
-
Publication number: 20090202531Abstract: Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided.Type: ApplicationFiled: November 1, 2006Publication date: August 13, 2009Applicants: Novartis AG, XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Publication number: 20090117111Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: ApplicationFiled: November 1, 2006Publication date: May 7, 2009Inventors: Sharon Lea Aukerman, Mohammad Luqman